Civil society groups have urged @who.int member states to “continue to advance a pandemic agreement #INB12 that can lay the essential groundwork for equitable, collective preparedness and response” for #WHA78.
✍️ @kerrycullinan.bsky.social
#Mpox | #H5N1
6/ 🌍 While we are negotiating a new #PandemicAccord at #INB12 this situation makes us think of the critical pieces:
-Improving surveillance capacity everywhere;
-Stenghtening health systems and progress towards #UHC
-Ensure equitable access to pandemic countermeasures
#GlobalHealth
Politico: Pandemic deal negotiators have just wrapped up talks for the year — and have only two more weeks planned to strike a deal before May 2025.
pro.politico.eu/news/pandemi... @who.int #INB12
4/ At #INB12, provisions on PABS continue to divide delegations. Developing countries demand conditionalities for pathogen data use, while others resist traceability and accountability measures, citing operational challenges. #PandemicPreparedness
3/ Last week’s #INB12 resumed negotiations reflect similar tensions: disagreements over Pathogen Access and Benefit Sharing (PABS), technology transfer, and sovereignty remain key obstacles to consensus. #GlobalHealthDiplomacy #GlobalHealth #PandemicAccord
1/ @mbarber.bsky.social's latest article in @plosgph.bsky.social offers a fascinating lens on the history of @who.int’s role in technology transfer: particularly timely as countries navigate contentious negotiations on the #PandemicAccord at #INB12.
🔗 journals.plos.org/globalpublic...
#GlobalHealth
Rancor Over Disagreement On Prevention Obligations in Pandemic Agreement Talks, Withholds Progress in Key Areas "There are interpretations, and there are interpretations. Trying to decipher closed door negotiations, brings to mind Akira Kurosawa's 1950 classic “Rashomon”." @who.int #INB12
• This Pandemic Agreement is our opportunity to right past wrongs and build a better foundation for a more resilient global health architecture rooted in solidarity and equity. • In this regard, we appreciate strong voice from civil society organizations in support for meaningful legal provisions in the Agreement and we encourage them to continue engaging with us and helping us keep on track towards our collective goal. • We have made some progress during INB-12 and this resumed session, but much work needs to be done to operationalize equity, including on key provisions of Articles 11, 12, 13, and 13bis, which our Group considers very critical to our objectives. • We want to see a stronger commitment on transfer of technology, including to make available licenses for pandemic-related health technologies, and support measures to scale-up the manufacturing of pandemic-related health products. • We need to see a safe, accountable, and transparent PABS System resulting from this Agreement.
• We also underline our commitment to prevention as one of the pillars of this Agreement. We stand ready to explore options on Article 4 that would take us forward, including by looking back at the text from the INB-9 that Ambassador Honsei and co-facilitators from the UK, India and Tanzania worked so hard on as a basis for further discussion towards a compromise solution. We hope others will engage in this discussion. • Time may be limited, but it should not constrain our efforts. Every remaining moment should be used to deepen engagement, better understand one another’s positions, and work towards convergence on the most challenging issues, including by making full use of the intersessional period. • The Group urges all Members not to force tying the fate of our collective efforts to a specific part of article/provision in the text that has not secured broad agreement among Members. • The Group for Equity approaches these negotiations with only the best intentions: to ensure the best possible outcomes for all peoples. We know that all of us share this commitment. Together, we can build a future where access to life-saving tools to prevent, prepare for, and respond to pandemics are no longer a privilege reserved for some, but guaranteed for all. • Our communication channels remain open to all who share these goals and are willing to work with us to achieve them.
Indonesia: "We want to see a stronger commitment on transfer of technology, including to make available licenses for pandemic-related health technologies, and support measures to scale-up the manufacturing of pandemic-related health products." @who.int @unitaidngos.bsky.social #INB12
"We appreciate strong voices from civil society organizations for meaningful legal provisions in the agreement and we encourage them to continue engaging with us and helping us keep on track towards our collective goal."
#INB12 Indonesia (on behalf of the Group for Equity): "However, compromise works best when reciprocated especially if our goal is to craft a robust meaningful and transformative Agreement." @who.int
United Republic of Tanzania
#INB12 The United Republic of Tanzania delivered a statement on behalf of the 47 member states of the African Region. @who.int
#INB12 Australia speaking on behalf of: Australia, Brazil, Canada, Colombia, Ethiopia, Indonesia, Malaysia, Mexico, Norway, Pakistan, the Philippines, Tanzania, and the United Kingdom. @who.int
Anne-Claire Amprou, Ambassador for Global Health, France
"Each Party shall develop and implement national and/ or regional policies, adapted to its domestic circumstances, regarding the inclusion of provisions in publicly funded research and development grants, contracts, and other similar funding arrangements, particularly with private entities and public-private partnerships, for the development of pandemic-related health products, that promote timely and equitable access to such products, particularly for developing countries, during public health emergencies of international concern including pandemic emergencies, and regarding the publication of such provisions. Such provisions may include: (i) licensing and/or sublicensing, particularly to manufacturers of developing countries and for the benefit of developing countries, preferably on a non-exclusive basis; (ii) affordable pricing policies; (iii) technology transfer; (iv) publication of relevant information on clinical trial protocols and relevant research results; and (v) adherence to product allocation frameworks adopted by WHO."
"The Parties shall strengthen sustainable and predictable financing to the extent feasible, in an inclusive and transparent manner, for implementation of this Agreement."
4. The Conference of the Parties shall take appropriate measures to give effect to this Article, including the possibility of exploring additional financial resources to support the implementation of this Agreement, through all sources of funding, existing and new, including innovative and those beyond official development assistance. 5. The Conference of the Parties shall periodically consider, as appropriate, the financial and implementation strategy for the Pandemic Agreement referred to in paragraph 3(a) of this Article. The Parties shall endeavour to align with it, as appropriate, when providing external financial support for the strengthening of pandemic prevention, preparedness and response.
#INB12 co-chair, Anne-Claire Amprou, hailed the progress made on Article 9 (Research and development) and Article 20 (Sustainable financing). @who.int @unitaid.bsky.social
1️⃣ @who.int Member States (MS) wrapped #INB12 pandemic agreement negotiations today. While they didn’t green the full text, they agreed on 2 key articles — Art. 9 (R&D) & Art. 20 (financing) — and continued exploring compromises on tech transfers, PABS, & distributed manufacturing.
Hello from Geneva after #INB12 negotiations have wrapped. Here’s our recap 🧵 of Day 5️⃣ (final day!) 👇
Ambassador Anne-Claire Amprou (France), Co-chair of the WHO Intergovernmental Negotiating Body to draft and negotiate a WHO convention, agreement or other international instrument on pandemic prevention, preparedness and response
Nina Jamal, Four Paws
Dame Barbara Stocking
James Love, Knowledge Ecology International , expounded on transparency and EU voting rights.
#INB12 6 December 2024 @who.int
8️⃣ As we look to the conclusion of #INB12 tomorrow and negotiators moving from 2024 to 2025, one thing is clear: MUCH WORK REMAINS TO BE DONE.
1️⃣ @WHO Member States (MS) are approaching the end of #INB12 with progress on greening text minimal.
Hello again. #INB12 negotiations on the pandemic agreement continued today, here’s our recap 🧵 of Day 4️⃣👇
James Love, KEI
Nithin Ramakrishnan, TWN
Pedro Villardi, PSI
Nina Jamal, Four Paws
#INB12 Thursday, 5 December 2024
The INB will discuss Chapter III, Articles 21, 13, 13bis, 11, and 20.
#INB12 Programme of work for Thursday, 5 December 2024
Stay tuned tomorrow for more daily recaps as we cover #INB12 cont. this week…
1️⃣ At the midpoint of this week's #INB12 negotiations, progress has been minimal as negotiators tackle the most contentious issues and struggle to find common ground. This morning, INB Co-Chair Dr. Matsoso indicated that concluding negotiations this year may not be achievable.
Knowledge Ecology International intervening on Article 11 on technology transfer and know-how. In our statement, KEI cited the FT's story from 19 November 2024: EU to demand technology transfers from Chinese companies
#INB12 3 December 2024 - Caption this @manonress.bsky.social @arianna-s.bsky.social @ellenthoen.bsky.social
"The Parties shall cooperate, as appropriate, to build, strengthen and sustain geographically diverse capacities and institutions for research and development, particularly in developing countries, and shall promote research collaboration, access to research, and rapid sharing of research information and results, especially during public health emergencies of international concern, including pandemic emergencies."
9.3 Each Party shall, in accordance with their national or domestic circumstances and law, and taking into account relevant national and international ethical guidelines and guidance, promote, during public health emergencies of international concern and pandemic emergencies, the conduct of well-designed and well-implemented clinical trials in their jurisdiction, including by: (i) promoting representative trial populations; (ii) promoting, as appropriate, sharing of pandemic-related vaccines, therapeutics and diagnostics for use as comparator products FN in the conduct of clinical trials of pandemic-related vaccines, therapeutics and diagnostics; (iii) promoting access to safe and effective products that result from these trials for such trial populations and for populations at risk in their communities. FOOTNOTE: For the purposes of this paragraph, “comparator product” means an investigational or marketed product (i.e., active control), or placebo, used as a reference in a clinical trial
10.3 WHO shall, upon request of the Conference of the Parties, provide assistance to the facilities referenced under paragraph 2 above, including, as appropriate, with respect to training, capacity-building, and timely support for development and production of pandemic-related products, especially in developing countries, with the aim to achieve geographically diversified production.
![ALT “Transfer of Technology refers to a [consensual/voluntary and] collaborative process where technology required to manufacture a product is transferred successfully on mutually agreed terms. This understanding is without prejudice to and does not affect the measures that Parties may take in accordance with their domestic or national legislation, provided that these measures [comply with their international obligations on intellectual property] / [comply with international rights, obligations and flexibilities on intellectual property under WIPO and WTO].”](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:aecv4ejztgiv64dhygwopm2h/bafkreiaghfyfdm4tjdcfbry6tanx2c62dv3luuszpmoqdwk6r6aahls7ee)
ALT “Transfer of Technology refers to a [consensual/voluntary and] collaborative process where technology required to manufacture a product is transferred successfully on mutually agreed terms. This understanding is without prejudice to and does not affect the measures that Parties may take in accordance with their domestic or national legislation, provided that these measures [comply with their international obligations on intellectual property] / [comply with international rights, obligations and flexibilities on intellectual property under WIPO and WTO].”
#INB12 Articles 9 and 10 have been "greened".
4 December 2024: 20, 4, 5, and 12. 5 December 2024: Chapter III, Article 21, 13 and 13 bis, and Chapter III
#INB12 Updated schedule for Wednesday, 4 December 2024 and Thursday, 5 December 2024. @who.int
